{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T22:18:56Z","timestamp":1772057936247,"version":"3.50.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T00:00:00Z","timestamp":1658275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T00:00:00Z","timestamp":1658275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Amyloid-beta (A\u03b2) deposition is common in cognitively unimpaired (CU) elderly &gt;85 years. This study investigated amyloid distribution and evaluated three published in vivo amyloid-PET staging schemes from a cognitively unimpaired (CU) cohort aged 84.9\u2009\u00b1\u20094.3 years (<jats:italic>n<\/jats:italic>\u2009=\u200975). SUV-based principal component analysis (PCA) was applied to <jats:sup>18<\/jats:sup>F-flutemetamol PET data to determine an unbiased regional covariance pattern of tracer uptake across grey matter regions. PET staging schemes were applied to the data and compared to the PCA output. Concentration of p-tau181 was measured in blood plasma. The PCA revealed three distinct components accounting for 91.2% of total SUV variance. PC1 driven by the large common variance of uptake in neocortical and striatal regions was significantly positively correlated with global SUVRs, APOE4 status and p-tau181 concentration. PC2 represented mainly non-specific uptake in typical amyloid-PET reference regions, and PC3 the occipital lobe. Application of the staging schemes demonstrated that the majority of the CU cohort (up to 93%) were classified as having pathological amount and distribution of A\u03b2. Good correspondence existed between binary (+\/\u2212) classification and later amyloid stages, however, substantial differences existed between schemes for low stages with 8\u201317% of individuals being unstageable, i.e., not following the sequential progression of A\u03b2 deposition. In spite of the difference in staging outcomes there was broad spatial overlap between earlier stages and PC1, most prominently in default mode network regions. This study critically evaluated the utility of in vivo amyloid staging from a single PET scan in CU elderly and found that early amyloid stages could not be consistently classified. The majority of the cohort had pathological A\u03b2, thus, it remains an open topic what constitutes abnormal brain A\u03b2 in the oldest-old and what is the best method to determine that.<\/jats:p>","DOI":"10.1038\/s41380-022-01685-6","type":"journal-article","created":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T07:02:52Z","timestamp":1658300572000},"page":"4335-4342","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Evaluation of in vivo staging of amyloid deposition in cognitively unimpaired elderly aged 78\u201394"],"prefix":"10.1038","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5946-123X","authenticated-orcid":false,"given":"Malgorzata M.","family":"Michalowska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8658-0151","authenticated-orcid":false,"given":"Karl","family":"Herholz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7808-9207","authenticated-orcid":false,"given":"Rainer","family":"Hinz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chinenye","family":"Amadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7660-2284","authenticated-orcid":false,"given":"Lynn","family":"McInnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose M.","family":"Anton-Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1422-4358","authenticated-orcid":false,"given":"Thomas K.","family":"Karikari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3930-4354","authenticated-orcid":false,"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas J.","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Pendleton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9080-519X","authenticated-orcid":false,"given":"Stephen F.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,20]]},"reference":[{"key":"1685_CR1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","volume":"12","author":"CR Jack Jr","year":"2013","unstructured":"Jack CR Jr., Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207\u201316.","journal-title":"Lancet Neurol"},{"key":"1685_CR2","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2015.4668","volume":"313","author":"WJ Jansen","year":"2015","unstructured":"Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313:1924\u201338.","journal-title":"JAMA"},{"key":"1685_CR3","doi-asserted-by":"crossref","unstructured":"Hameed S, Fuh J-L, Senanarong V, Ebenezer EGM, Looi I, Dominguez J, et al. Role of fluid biomarkers and PET imaging in early diagnosis and its clinical implication in the management of Alzheimer\u2019s disease. J Alzheimer\u2019s Dis Rep. 2020;4:1\u201317.","DOI":"10.3233\/ADR-190143"},{"key":"1685_CR4","first-page":"25","volume":"9","author":"S Salloway","year":"2017","unstructured":"Salloway S, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, et al. Performance of [18F] flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer\u2019s disease. Alzheimer\u2019s Dement: Diagn Assess Dis Monit. 2017;9:25\u201334.","journal-title":"Alzheimer\u2019s Dement: Diagn Assess Dis Monit"},{"key":"1685_CR5","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1212\/WNL.58.12.1791","volume":"58","author":"DR Thal","year":"2002","unstructured":"Thal DR, R\u00fcb U, Orantes M, Braak H. Phases of A\u03b2-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791\u2013800.","journal-title":"Neurology"},{"key":"1685_CR6","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/ana.24711","volume":"80","author":"H Cho","year":"2016","unstructured":"Cho H, Choi JY, Hwang MS, Kim YJ, Lee HM, Lee HS, et al. In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann Neurol. 2016;80:247\u201358.","journal-title":"Ann Neurol"},{"key":"1685_CR7","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00401-018-1897-9","volume":"136","author":"DR Thal","year":"2018","unstructured":"Thal DR, Beach TG, Zanette M, Lilja J, Heurling K, Chakrabarty A, et al. Estimation of amyloid distribution by [18 F] flutemetamol PET predicts the neuropathological phase of amyloid \u03b2-protein deposition. Acta Neuropathol. 2018;136:557\u201367.","journal-title":"Acta Neuropathol"},{"key":"1685_CR8","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1212\/WNL.0000000000004643","volume":"89","author":"MJ Grothe","year":"2017","unstructured":"Grothe MJ, Barthel H, Sepulcre J, Dyrba M, Sabri O, Teipel SJ, et al. In vivo staging of regional amyloid deposition. Neurology. 2017;89:2031\u20138.","journal-title":"Neurology"},{"key":"1685_CR9","doi-asserted-by":"crossref","first-page":"4219","DOI":"10.1002\/hbm.25121","volume":"41","author":"I Jelistratova","year":"2020","unstructured":"Jelistratova I, Teipel SJ, Grothe MJ. Longitudinal validity of PET-based staging of regional amyloid deposition. Hum Brain Mapp. 2020;41:4219\u201331.","journal-title":"Hum Brain Mapp"},{"key":"1685_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-018-0453-0","volume":"11","author":"FA Sakr","year":"2019","unstructured":"Sakr FA, Grothe MJ, Cavedo E, Jelistratova I, Habert M-O, Dyrba M, et al. Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study. Alzheimer\u2019s Res Ther. 2019;11:1\u201311.","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"1685_CR11","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jamaneurol.2019.2214","volume":"76","author":"N Mattsson","year":"2019","unstructured":"Mattsson N, Palmqvist S, Stomrud E, Vogel J, Hansson O. Staging \u03b2-amyloid pathology with amyloid positron emission tomography. JAMA Neurol. 2019;76:1319\u201329.","journal-title":"JAMA Neurol"},{"key":"1685_CR12","doi-asserted-by":"crossref","unstructured":"Teipel SJ, Temp AG, Levin F, Dyrba M, Grothe MJ, Initiative AsDN. Association of PET\u2010based stages of amyloid deposition with neuropathological markers of A\u03b2 pathology. Ann Clin Transl Neurol. 8:29\u201342;2021.","DOI":"10.1002\/acn3.51238"},{"key":"1685_CR13","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/00002093-199910000-00009","volume":"13","author":"DS Wolf","year":"1999","unstructured":"Wolf DS, Gearing M, Snowdon DA, Mori H, Markesbery WR, Mirra SS. Progression of regional neuropathology in Alzheimer disease and normal elderly: findings from the Nun study. Alzheimer Dis Assoc Disord. 1999;13:226\u201331.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"1685_CR14","doi-asserted-by":"crossref","first-page":"e2031654","DOI":"10.1001\/jamanetworkopen.2020.31654","volume":"4","author":"N Beker","year":"2021","unstructured":"Beker N, Ganz A, Hulsman M, Klausch T, Schmand BA, Scheltens P, et al. Association of cognitive function trajectories in centenarians with postmortem neuropathology, physical health, and other risk factors for cognitive decline. JAMA Netw Open. 2021;4:e2031654.","journal-title":"JAMA Netw Open"},{"key":"1685_CR15","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s12013-010-9093-0","volume":"58","author":"C Habeck","year":"2010","unstructured":"Habeck C, Stern Y. Multivariate data analysis for neuroimaging data: overview and application to Alzheimer\u2019s disease. Cell Biochem Biophys. 2010;58:53\u201367.","journal-title":"Cell Biochem Biophys"},{"key":"1685_CR16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/hbm.10069","volume":"18","author":"G Zuendorf","year":"2003","unstructured":"Zuendorf G, Kerrouche N, Herholz K, Baron JC. Efficient principal component analysis for multivariate 3D voxel\u2010based mapping of brain functional imaging data sets as applied to FDG\u2010PET and normal aging. Hum Brain Mapp. 2003;18:13\u201321.","journal-title":"Hum Brain Mapp"},{"key":"1685_CR17","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/sj.jcbfm.9600296","volume":"26","author":"N Kerrouche","year":"2006","unstructured":"Kerrouche N, Herholz K, Mielke R, Holthoff V, Baron J-C. 18FDG PET in vascular dementia: differentiation from Alzheimer\u2019s disease using voxel-based multivariate analysis. J Cereb Blood Flow Metab. 2006;26:1213\u201321.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1685_CR18","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.neuroimage.2008.07.053","volume":"43","author":"J Fripp","year":"2008","unstructured":"Fripp J, Bourgeat P, Acosta O, Raniga P, Modat M, Pike KE, et al. Appearance modeling of 11C PiB PET images: characterizing amyloid deposition in Alzheimer\u2019s disease, mild cognitive impairment and healthy aging. Neuroimage. 2008;43:430\u20139.","journal-title":"Neuroimage"},{"key":"1685_CR19","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2967\/jnumed.118.207811","volume":"60","author":"J Lilja","year":"2019","unstructured":"Lilja J, Leuzy A, Chiotis K, Savitcheva I, S\u00f6rensen J, Nordberg A. Spatial normalization of 18F-flutemetamol PET images using an adaptive principal-component template. J Nucl Med. 2019;60:285\u201391.","journal-title":"J Nucl Med"},{"key":"1685_CR20","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3233\/JAD-180171","volume":"64","author":"AC Robinson","year":"2018","unstructured":"Robinson AC, Davidson YS, Horan MA, Pendleton N, Mann D. Pathological correlates of cognitive impairment in the University of Manchester longitudinal study of cognition in normal healthy old age. J Alzheimer\u2019s Dis. 2018;64:483\u201396.","journal-title":"J Alzheimer\u2019s Dis"},{"key":"1685_CR21","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13195-018-0406-7","volume":"10","author":"E Konijnenberg","year":"2018","unstructured":"Konijnenberg E, Carter SF, Ten Kate M, Den Braber A, Tomassen J, Amadi C, et al. The EMIF-AD PreclinAD study: study design and baseline cohort overview. Alzheimer\u2019s Res Ther. 2018;10:75.","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"1685_CR22","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1109\/TMI.2013.2261313","volume":"32","author":"SH Keller","year":"2013","unstructured":"Keller SH, Svarer C, Sibomana M. Attenuation correction for the HRRT PET-scanner using transmission scatter correction and total variation regularization. IEEE Trans Med Imaging. 2013;32:1611\u201321.","journal-title":"IEEE Trans Med Imaging"},{"key":"1685_CR23","doi-asserted-by":"crossref","unstructured":"Sibomana M, Byars L, Panin V, Lenox M, Kehren F, Rist J, et al. Simultaneous measurement of transmission and emission contamination using a collimated \/sup 137\/Cs point source for the HRRT. Nuclear Science Symposium Conference Record, 2004 IEEE. 2004;4:2647\u201351.","DOI":"10.1109\/NSSMIC.2004.1462795"},{"key":"1685_CR24","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.2967\/jnumed.107.045351","volume":"49","author":"FC Sureau","year":"2008","unstructured":"Sureau FC, Reader AJ, Comtat C, Leroy C, Ribeiro MJ, Buvat I, et al. Impact of image-space resolution modeling for studies with the high-resolution research tomograph. J Nucl Med. 2008;49:1000\u20138.","journal-title":"J Nucl Med"},{"key":"1685_CR25","doi-asserted-by":"publisher","unstructured":"Comtat C, Sureau FC, Sibomana M, Hong IK, Sjoholm N, Trebossen R. Image based resolution modeling for the HRRT OSEM reconstructions software. Proceedings of the 2008 IEEE Nuclear Science Symposium Conference Record; 19\u201325 Oct. 2008. p. 4120\u20133. https:\/\/doi.org\/10.1109\/NSSMIC.2008.4774188.","DOI":"10.1109\/NSSMIC.2008.4774188"},{"key":"1685_CR26","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1109\/42.363108","volume":"13","author":"HM Hudson","year":"1994","unstructured":"Hudson HM, Larkin RS. Accelerated image reconstruction using ordered subsets of projection data. IEEE Trans Med Imaging. 1994;13:601\u20139.","journal-title":"IEEE Trans Med Imaging"},{"key":"1685_CR27","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1109\/TMI.2007.892644","volume":"26","author":"IK Hong","year":"2007","unstructured":"Hong IK, Chung ST, Kim HK, Kim YB, Son YD, Cho ZH. Ultra fast symmetry and SIMD-based projection-backprojection (SSP) algorithm for 3-D PET image reconstruction. IEEE Trans Med Imaging. 2007;26:789\u2013803.","journal-title":"IEEE Trans Med Imaging"},{"key":"1685_CR28","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","volume":"141","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ, Pascoal TA, Karikari TK, Benedet AL, Lantero-Rodriguez J, Brinkmalm G, et al. Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology. Acta Neuropathol. 2021;141:709\u201324.","journal-title":"Acta Neuropathol"},{"key":"1685_CR29","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19:422\u201333.","journal-title":"Lancet Neurol"},{"key":"1685_CR30","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41380-020-00923-z","volume":"26","author":"TK Karikari","year":"2021","unstructured":"Karikari TK, Benedet AL, Ashton NJ, Lantero Rodriguez J, Snellman A, Suarez-Calvet M, et al. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer\u2019s disease neuroimaging initiative. Mol Psychiatry. 2021;26:429\u201342.","journal-title":"Mol Psychiatry"},{"key":"1685_CR31","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/hbm.20254","volume":"28","author":"A Hammers","year":"2007","unstructured":"Hammers A, Chen CH, Lemieux L, Allom R, Vossos S, Free SL, et al. Statistical neuroanatomy of the human inferior frontal gyrus and probabilistic atlas in a standard stereotaxic space. Hum Brain Mapp. 2007;28:34\u201348.","journal-title":"Hum Brain Mapp"},{"key":"1685_CR32","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.neuroimage.2006.01.021","volume":"31","author":"RS Desikan","year":"2006","unstructured":"Desikan RS, Segonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31:968\u201380.","journal-title":"Neuroimage"},{"key":"1685_CR33","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.neuroimage.2007.07.007","volume":"38","author":"J Ashburner","year":"2007","unstructured":"Ashburner J. A fast diffeomorphic image registration algorithm. Neuroimage. 2007;38:95\u2013113.","journal-title":"Neuroimage"},{"key":"1685_CR34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous Sr MD, Jagust WJ, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimer\u2019s Dement. 2015;11:1\u201315. e14.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1685_CR35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13195-019-0478-z","volume":"11","author":"G Salvado","year":"2019","unstructured":"Salvado G, Molinuevo JL, Brugulat-Serrat A, Falcon C, Grau-Rivera O, Suarez-Calvet M, et al. Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. Alzheimers Res Ther. 2019;11:27.","journal-title":"Alzheimers Res Ther"},{"key":"1685_CR36","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jalz.2018.09.001","volume":"15","author":"R La Joie","year":"2019","unstructured":"La Joie R, Ayakta N, Seeley WW, Borys E, Boxer AL, DeCarli C, et al. Multisite study of the relationships between antemortem [(11)C]PIB-PET Centiloid values and postmortem measures of Alzheimer\u2019s disease neuropathology. Alzheimers Dement. 2019;15:205\u201316.","journal-title":"Alzheimers Dement"},{"key":"1685_CR37","unstructured":"Beaumont R. An introduction to principal component analysis & factor analysis using SPSS 19 and R (psych package). Factor Analysis and Principal Component Analysis (PCA). 2012;24."},{"key":"1685_CR38","doi-asserted-by":"crossref","first-page":"166","DOI":"10.2967\/jnumed.119.235879","volume":"61","author":"E Fantoni","year":"2020","unstructured":"Fantoni E, Collij L, Alves IL, Buckley C, Farrar G. The spatial-temporal ordering of amyloid pathology and opportunities for PET imaging. J Nucl Med. 2020;61:166\u201371.","journal-title":"J Nucl Med"},{"key":"1685_CR39","doi-asserted-by":"crossref","first-page":"13018","DOI":"10.1073\/pnas.1713215114","volume":"114","author":"J Rasmussen","year":"2017","unstructured":"Rasmussen J, Mahler J, Beschorner N, Kaeser SA, Hasler LM, Baumann F, et al. Amyloid polymorphisms constitute distinct clouds of conformational variants in different etiological subtypes of Alzheimer\u2019s disease. Proc Natl Acad Sci USA 2017;114:13018\u201323.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1685_CR40","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1212\/WNL.0b013e318245d295","volume":"78","author":"K Rodrigue","year":"2012","unstructured":"Rodrigue K, Kennedy K, Devous M, Rieck J, Hebrank A, Diaz-Arrastia R, et al. \u03b2-Amyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology. 2012;78:387\u201395.","journal-title":"Neurology"},{"key":"1685_CR41","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2174\/1567205017666201229113416","volume":"17","author":"DW Kang","year":"2020","unstructured":"Kang DW, Wang S-M, Na H-R, Lee CU, Baek I-H, Lim HK. Differential effects of the interaction between the education and APOE \u03b54 allele on amyloid-beta retention and memory performances in cognitively normal older adults and Alzheimer\u2019s disease patients. Curr Alzheimer Res. 2020;17:1023\u201332.","journal-title":"Curr Alzheimer Res"},{"key":"1685_CR42","doi-asserted-by":"crossref","first-page":"015001","DOI":"10.1088\/2057-1976\/1\/1\/015001","volume":"1","author":"M Goryawala","year":"2015","unstructured":"Goryawala M, Duara R, Loewenstein DA, Zhou Q, Barker W, Adjouadi M, et al. Apolipoprotein-E4 (ApoE4) carriers show altered small-world properties in the default mode network of the brain. Biomed Phys Eng Express. 2015;1:015001.","journal-title":"Biomed Phys Eng Express"},{"key":"1685_CR43","first-page":"231","volume":"8","author":"X Wu","year":"2016","unstructured":"Wu X, Li Q, Yu X, Chen K, Fleisher AS, Guo X, et al. A triple network connectivity study of large-scale brain systems in cognitively normal APOE4 carriers. Front Aging Neurosci. 2016;8:231.","journal-title":"Front Aging Neurosci"},{"key":"1685_CR44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-01150-x","volume":"8","author":"S Palmqvist","year":"2017","unstructured":"Palmqvist S, Sch\u00f6ll M, Strandberg O, Mattsson N, Stomrud E, Zetterberg H, et al. Earliest accumulation of \u03b2-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nat Commun. 2017;8:1\u201313.","journal-title":"Nat Commun"},{"key":"1685_CR45","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3389\/fnagi.2020.00046","volume":"12","author":"FC Quevenco","year":"2020","unstructured":"Quevenco FC, van Bergen JM, Treyer V, Studer ST, Kagerer SM, Meyer R, et al. Functional brain network connectivity patterns associated with normal cognition at old-age, local \u03b2-amyloid, Tau, and APOE4. Front Aging Neurosci. 2020;12:46.","journal-title":"Front Aging Neurosci"},{"key":"1685_CR46","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1177\/1533317517698795","volume":"32","author":"DB Hammers","year":"2017","unstructured":"Hammers DB, Atkinson TJ, Dalley BC, Suhrie KR, Horn KP, Rasmussen KM, et al. Amyloid positivity using [18F] flutemetamol-PET and cognitive deficits in nondemented community-dwelling older adults. Am J Alzheimer\u2019s Dis Other Dement\u00ae. 2017;32:320\u20138.","journal-title":"Am J Alzheimer\u2019s Dis Other Dement\u00ae"},{"key":"1685_CR47","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1080\/13803395.2012.763113","volume":"35","author":"RJ Melrose","year":"2013","unstructured":"Melrose RJ, Harwood D, Khoo T, Mandelkern M, Sultzer DL. Association between cerebral metabolism and Rey\u2013Osterrieth complex figure test performance in Alzheimer\u2019s disease. J Clin Exp Neuropsychol. 2013;35:246\u201358.","journal-title":"J Clin Exp Neuropsychol"},{"key":"1685_CR48","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1016\/j.neuropsychologia.2011.10.010","volume":"49","author":"H-J Ahn","year":"2011","unstructured":"Ahn H-J, Seo SW, Chin J, Suh MK, Lee BH, Kim ST, et al. The cortical neuroanatomy of neuropsychological deficits in mild cognitive impairment and Alzheimer\u2019s disease: a surface-based morphometric analysis. Neuropsychologia. 2011;49:3931\u201345.","journal-title":"Neuropsychologia"},{"key":"1685_CR49","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.neurobiolaging.2007.06.010","volume":"30","author":"E Salmon","year":"2009","unstructured":"Salmon E, Kerrouche N, Perani D, Lekeu F, Holthoff V, Beuthien-Baumann B, et al. On the multivariate nature of brain metabolic impairment in Alzheimer\u2019s disease. Neurobiol Aging. 2009;30:186\u201397.","journal-title":"Neurobiol Aging"},{"key":"1685_CR50","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3233\/JAD-2010-100156","volume":"23","author":"VD Santos","year":"2011","unstructured":"Santos VD, Thomann PA, W\u00fcstenberg T, Seidl U, Essig M, Schr\u00f6der J. Morphological cerebral correlates of CERAD test performance in mild cognitive impairment and Alzheimer\u2019s disease. J Alzheimer\u2019s Dis. 2011;23:411\u201320.","journal-title":"J Alzheimer\u2019s Dis"},{"key":"1685_CR51","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","volume":"71","author":"PT Nelson","year":"2012","unstructured":"Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71:362\u201381.","journal-title":"J Neuropathol Exp Neurol"},{"key":"1685_CR52","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1007\/s00259-015-3115-5","volume":"42","author":"K Chiotis","year":"2015","unstructured":"Chiotis K, Carter SF, Farid K, Savitcheva I, Nordberg A. Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging. Eur J Nucl Med Mol imaging. 2015;42:1492\u2013506.","journal-title":"Eur J Nucl Med Mol imaging"},{"key":"1685_CR53","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.jalz.2018.06.1353","volume":"14","author":"M Navitsky","year":"2018","unstructured":"Navitsky M, Joshi AD, Kennedy I, Klunk WE, Rowe CC, Wong DF, et al. Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale. Alzheimers Dement. 2018;14:1565\u201371.","journal-title":"Alzheimers Dement"},{"key":"1685_CR54","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/WCO.0000000000000910","volume":"34","author":"CH Kawas","year":"2021","unstructured":"Kawas CH, Legdeur N, Corrada MM. What have we learned from cognition in the oldest-old. Curr Opin Neurol. 2021;34:258\u201365.","journal-title":"Curr Opin Neurol"},{"key":"1685_CR55","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3233\/JAD-201578","volume":"82","author":"DC Woodworth","year":"2021","unstructured":"Woodworth DC, Scambray KA, Corrada MM, Kawas CH, Sajjadi SA. Neuroimaging in the oldest-old: a review of the literature. J Alzheimers Dis. 2021;82:129\u201347.","journal-title":"J Alzheimers Dis"},{"key":"1685_CR56","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1212\/WNL.0b013e31828c2fc8","volume":"80","author":"BE Snitz","year":"2013","unstructured":"Snitz BE, Weissfeld LA, Lopez OL, Kuller LH, Saxton J, Singhabahu DM, et al. Cognitive trajectories associated with beta-amyloid deposition in the oldest-old without dementia. Neurology. 2013;80:1378\u201384.","journal-title":"Neurology"},{"key":"1685_CR57","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0197-4580(97)00056-0","volume":"18","author":"H Braak","year":"1997","unstructured":"Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18:351\u20137.","journal-title":"Neurobiol Aging"},{"key":"1685_CR58","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.neuron.2016.01.028","volume":"89","author":"M Scholl","year":"2016","unstructured":"Scholl M, Lockhart SN, Schonhaut DR, O\u2019Neil JP, Janabi M, Ossenkoppele R, et al. PET imaging of Tau deposition in the aging human brain. Neuron. 2016;89:971\u201382.","journal-title":"Neuron"},{"key":"1685_CR59","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1016\/j.neurobiolaging.2012.02.008","volume":"33","author":"H Oh","year":"2012","unstructured":"Oh H, Madison C, Haight TJ, Markley C, Jagust WJ. Effects of age and beta-amyloid on cognitive changes in normal elderly people. Neurobiol Aging. 2012;33:2746\u201355.","journal-title":"Neurobiol Aging"},{"key":"1685_CR60","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/d41586-021-01546-2","volume":"594","author":"A Mullard","year":"2021","unstructured":"Mullard A. Landmark Alzheimer\u2019s drug approval confounds research community. Nature. 2021;594:309\u201310.","journal-title":"Nature"},{"key":"1685_CR61","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/s41582-021-00540-6","volume":"17","author":"J Karlawish","year":"2021","unstructured":"Karlawish J, Grill JD. The approval of Aduhelm risks eroding public trust in Alzheimer research and the FDA. Nat Rev Neurol. 2021;17:523\u20134.","journal-title":"Nat Rev Neurol"},{"key":"1685_CR62","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41582-021-00557-x","volume":"17","author":"KY Liu","year":"2021","unstructured":"Liu KY, Howard R. Can we learn lessons from the FDA\u2019s approval of aducanumab? Nat Rev Neurol. 2021;17:715\u201322.","journal-title":"Nat Rev Neurol"},{"key":"1685_CR63","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1126\/science.abi6401","volume":"373","author":"DJ Selkoe","year":"2021","unstructured":"Selkoe DJ. Treatments for Alzheimer\u2019s disease emerge. Science. 2021;373:624\u20136.","journal-title":"Science"},{"key":"1685_CR64","doi-asserted-by":"crossref","unstructured":"Martens C, Debeir O, Decaestecker C, Metens T, Lebrun L, Leurquin-Sterk G, et al. Voxelwise principal component analysis of dynamic [S-Methyl-(11)C]Methionine PET data in glioma patients. Cancers. 2021;13:2342.","DOI":"10.3390\/cancers13102342"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-022-01685-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-022-01685-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-022-01685-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T10:48:48Z","timestamp":1680864528000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-022-01685-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,20]]},"references-count":64,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1685"],"URL":"https:\/\/doi.org\/10.1038\/s41380-022-01685-6","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,20]]},"assertion":[{"value":"28 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NJA has given lectures in symposia sponsored by Eli Lilly. KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, BioArctic, Biogen, JOMDD\/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Ono Pharma, Pharmatrophix, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. HZ has served at scientific advisory boards and\/or as a consultant for Abbvie, Alector, Annexon, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Pinteon Therapeutics, Red Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). The remaining authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Greater Manchester South Research Ethics Committee (ref: 14\/NW\/011). The participants provided written informed consent at the time of inclusion in the PreclinAD study from the European Medical Information Framework for AD (EMIF-AD). Previously published study providing details of recruitment and ethical considerations has been cited.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}